MedTrace Logo

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

NCT05909995 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-02-18

No results posted yet for this study

Summary

The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants with select solid tumors.

Conditions

  • Melanoma
  • Hepatocellular Carcinoma (HCC)
  • Renal Cell Carcinoma (RCC)
  • Microsatellite Instability - High (MSI-H)
  • Mismatch Repair Deficient (dMMR)
  • Colorectal Carcinoma (CRC)

Interventions

DRUG

INCB 99280 with Ipilimumab

Dose Escalation and expansion of INCB 99280 with Ipilimumab

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-29
Primary Completion
2024-09-19
Completion
2024-11-11
FDA Drug
Yes

Countries

  • United States
  • Canada
  • South Africa

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05909995 on ClinicalTrials.gov